<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0">
<channel>
<title>Dermatology Drug Views - Medical Information Health Drugs Conditions Pharmacy Pills</title>
<description>skin, hair, nails, face, mucous membrane, sexually, acne, warts, multiple inflammatory dermatoses, skin cancers, autoimmune diseases, occupational dermatoses, contact dermatitis, Drug Views, drugs, Medical, Information, Health, Drugs, Conditions, Pharmacy, Pills</description>
<link>http://www.drugviews.com/articles.php</link>
<language>en-us</language>
<generator>Ateom.com - Website Power Tools</generator>

<item>
<title>Halozyme initiates Ultrafast Insulin combination Phase 2 studies with rHuPH20</title>
<description><![CDATA[Halozyme Therapeutics, Inc. today announced the initiation of <A HREF='http://www.2daypharmacy.com/'>two</A> Phase 2 Ultrafast Insulin <A HREF='http://www.birthcontrol-drugs.com/'>treatment</A> studies that utilize its rHuPH20 hyaluronidase enzyme (PH20) in <A HREF='http://www.drugs-to-go.com/'>combination</A> with the <A HREF='http://www.2daypharmacy.com/'>two</A> leading commercially available mealtime analogs: insulin aspart, the active ingredient in NovoLog®, and insulin lispro, the active ingredient in Humalog®.]]></description>
<pubDate>Thu, 02 Sep 2010 08:13:00 -0400</pubDate>
<link>http://www.drugviews.com/articles.php?t=Halozyme-initiates-Ultrafast-Insulin-combination-Phase-2-studies-with-rHuPH20</link>
</item>

<item>
<title>Lytix Biopharma granted Hungarian approval for Lytixar Phase IIa clinical trial in Gram positive skin infections</title>
<description><![CDATA[The Norwegian pharmaceutical company Lytix Biopharma AS today announces the approval in Hungary to commence a Phase IIa clinical trial with Lytixar (LTX-109) <A HREF='http://www.birthcontrol-drugs.com/'>treatment</A> of skin <A HREF='http://www.amoxicillinrx.com/'>infections</A> caused by Gram <A HREF='http://www.healthcare-opportunity.com/'>positive</A> bacteria.]]></description>
<pubDate>Thu, 02 Sep 2010 07:17:00 -0400</pubDate>
<link>http://www.drugviews.com/articles.php?t=Lytix-Biopharma-granted-Hungarian-approval-for-Lytixar-Phase-IIa-clinical-trial-in-Gram-positive-skin-infections</link>
</item>

<item>
<title>FDA approves LUMIGAN eye drops for intraocular pressure reduction in open-angle glaucoma patients</title>
<description><![CDATA[Allergan, Inc. today announced the United States Food and Drug Administration (FDA) has approved LUMIGAN (bimatoprost ophthalmic solution) 0.01% as a first-line therapy indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.]]></description>
<pubDate>Thu, 02 Sep 2010 00:46:00 -0400</pubDate>
<link>http://www.drugviews.com/articles.php?t=FDA-approves-LUMIGAN-eye-drops-for-intraocular-pressure-reduction-in-open-angle-glaucoma-patients</link>
</item>

<item>
<title>Health Tip: Spot Symptoms of Ringworm</title>
<description><![CDATA[<A HREF='http://www.tramadolsideeffects.com/'>Warning</A> signs of the fungal <A HREF='http://www.online-antibiotics.info/'>infection</A>]]></description>
<pubDate>Tue, 31 Aug 2010 10:00:00 -0400</pubDate>
<link>http://www.drugviews.com/articles.php?t=Health-Tip-Spot-Symptoms-of-Ringworm</link>
</item>

<item>
<title>Study shows DERMACYTE Oxygen Concentrate improves skin appearance</title>
<description><![CDATA[Oxygen Biotherapeutics, Inc. today announced that results from an 8-week cosmetic study showed that the topical application of DERMACYTE Oxygen Concentrate, an oxygen-rich skin <A HREF='http://www.medicare-california.com/'>care</A> lotion, appears to improve the appearance of fine lines and the perception of skin appearance.]]></description>
<pubDate>Tue, 31 Aug 2010 08:18:29 -0400</pubDate>
<link>http://www.drugviews.com/articles.php?t=Study-shows-DERMACYTE-Oxygen-Concentrate-improves-skin-appearance</link>
</item>

<item>
<title>Halozyme identifies strategy to reintroduce HYLENEX</title>
<description><![CDATA[Halozyme Therapeutics, Inc. today announced the completion of its <A HREF='http://www.ondirectory.org/'>root</A> cause investigation regarding HYLENEX manufacturing and has identified a corrective action plan and regulatory strategy to reintroduce HYLENEX to the market. Halozyme and Baxter are finalizing the materials for a meeting with the U.S. Food and Drug Administration to seek concurrence with the reintroduction strategy.]]></description>
<pubDate>Tue, 31 Aug 2010 08:15:45 -0400</pubDate>
<link>http://www.drugviews.com/articles.php?t=Halozyme-identifies-strategy-to-reintroduce-HYLENEX</link>
</item>

<item>
<title>FDA extends Prescription Drug User Fee Act date for ezogabine</title>
<description><![CDATA[GlaxoSmithKline and Valeant Pharmaceuticals International announced today the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for ezogabine to 30 November 2010.]]></description>
<pubDate>Tue, 31 Aug 2010 00:47:00 -0400</pubDate>
<link>http://www.drugviews.com/articles.php?t=FDA-extends-Prescription-Drug-User-Fee-Act-date-for-ezogabine</link>
</item>

<item>
<title>The Hand Eczema Trial (HET): design of a randomised clinical trial of the effect of classification and individual counselling versus no intervention among health-care workers with hand eczema</title>
<description><![CDATA[We describe the design of a randomised clinical trial to investigate the effects of classification of hand eczema <A HREF='http://www.privacyplusprescriptions.com/'>plus</A> individual counselling versus no intervention. The trial includes <A HREF='http://www.your-prescriptions.com/'>health</A>-care workers with hand eczema identified from a self-administered questionnaire delivered to 3181 <A HREF='http://www.your-prescriptions.com/'>health</A>-care workers in three Danish hospitals. The questionnaire identifies the prevalence of hand eczema, knowledge of skin-protection, and exposures that can lead to hand ]]></description>
<pubDate>Mon, 30 Aug 2010 18:00:00 -0400</pubDate>
<link>http://www.drugviews.com/articles.php?t=The-Hand-Eczema-Trial-HET-design-of-a-randomised-clinical-trial-of-the-effect-of-classification-and-individual-counselling-ve</link>
</item>

<item>
<title>FDA approves additional strengths of SOLODYN for inflammatory lesions treatment</title>
<description><![CDATA[Medicis today announced that the U.S. Food and Drug Administration (FDA) has approved additional strengths of SOLODYN (minocycline HCl, USP) Extended Release Tablets in 55 mg, 80 mg and 105 mg dosages for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years of age and older.]]></description>
<pubDate>Mon, 30 Aug 2010 08:10:12 -0400</pubDate>
<link>http://www.drugviews.com/articles.php?t=FDA-approves-additional-strengths-of-SOLODYN-for-inflammatory-lesions-treatment</link>
</item>

<item>
<title>Filaggrin Null Mutations Increase the Risk and Persistence of Hand Eczema in Subjects With Atopic Dermatitis: Results From a General Population Study</title>
<description><![CDATA[This study examines whether null mutations of the filaggrin gene increases the risk of hand eczema in <A HREF='http://www.elidelrx.com/'>atopic</A> individuals.  The British Journal of Dermatology (Source: Medscape Today Headlines)]]></description>
<pubDate>Mon, 30 Aug 2010 06:36:54 -0400</pubDate>
<link>http://www.drugviews.com/articles.php?t=Filaggrin-Null-Mutations-Increase-the-Risk-and-Persistence-of-Hand-Eczema-in-Subjects-With-Atopic-Dermatitis-Results-From-a-Gen</link>
</item>

<item>
<title>Researchers develop microneedles to deliver quantum dots for skin cancer treatment</title>
<description><![CDATA[Researchers from North Carolina State University have developed extremely small microneedles that can be used to deliver medically-relevant nanoscale dyes called quantum dots into skin - an advance that opens the door to new techniques for diagnosing and treating a variety of <A HREF='http://www.eprescription-drug.com/'>medical</A> conditions, including skin <A HREF='http://www.tramadol-rx.com/'>cancer</A>.]]></description>
<pubDate>Thu, 26 Aug 2010 04:58:32 -0400</pubDate>
<link>http://www.drugviews.com/articles.php?t=Researchers-develop-microneedles-to-deliver-quantum-dots-for-skin-cancer-treatment</link>
</item>

<item>
<title>Prollenium enters supply and distribution partnership with Canderm for Ovita HV dermal filler</title>
<description><![CDATA[Prollenium and Canderm GP, an affiliate of sanofi-aventis Canada, have entered into a supply and distribution partnership for Ovita HV, a Hyaluronic Acid (HA) based dermal filler.]]></description>
<pubDate>Wed, 25 Aug 2010 02:36:03 -0400</pubDate>
<link>http://www.drugviews.com/articles.php?t=Prollenium-enters-supply-and-distribution-partnership-with-Canderm-for-Ovita-HV-dermal-filler</link>
</item>

<item>
<title>BMI linked to wheezing and eczema risk in childhood</title>
<description><![CDATA[Results from a UK <A HREF='http://www.drug-care.info/'>study</A> show that young children who are overweight are at increased risk for wheezing and eczema. (Source: MedWire News - Respiratory)]]></description>
<pubDate>Mon, 23 Aug 2010 19:00:00 -0400</pubDate>
<link>http://www.drugviews.com/articles.php?t=BMI-linked-to-wheezing-and-eczema-risk-in-childhood</link>
</item>

<item>
<title>Acetaminophen May Cause Asthma</title>
<description><![CDATA[]]></description>
<pubDate>Mon, 23 Aug 2010 00:00:00 -0400</pubDate>
<link>http://www.drugviews.com/articles.php?t=Acetaminophen-May-Cause-Asthma</link>
</item>

<item>
<title>CHIA confers susceptibility to childhood eczema</title>
<description><![CDATA[]]></description>
<pubDate>Sun, 22 Aug 2010 00:39:46 -0400</pubDate>
<link>http://www.drugviews.com/articles.php?t=CHIA-confers-susceptibility-to-childhood-eczema</link>
</item>

<item>
<title>Warner Chilcott adds $1.5 billion for senior secured credit facilities</title>
<description><![CDATA[Warner Chilcott plc today announced that it has completed an amendment to its existing senior secured <A HREF='http://www.stirx.net/'>credit</A> facilities, pursuant to which it has incurred an <A HREF='http://www.morerx.info/'>additional</A> $1.5 billion aggregate principal <A HREF='http://www.rxdiscountplus.com/'>amount</A> of new term loans]]></description>
<pubDate>Sat, 21 Aug 2010 01:09:18 -0400</pubDate>
<link>http://www.drugviews.com/articles.php?t=Warner-Chilcott-adds-1-5-billion-for-senior-secured-credit-facilities</link>
</item>

<item>
<title>Skin Condition Associated With Depression, Anxiety And Suicidal Feelings</title>
<description><![CDATA[Individuals with psoriasis appear to have an increased risk of <A HREF='http://www.zoloft-prescription.com/'>depression</A>, anxiety and suicidality, according to a report in the August issue of Archives of Dermatology, one of the JAMA/Archives journals. Psoriasis affects 1 percent to 3 percent of the <A HREF='http://www.drugpharmacist.com/'>general</A> population, and estimates suggest 0.4 percent to 2.3 percent of adults have the <A HREF='http://www.your-health-rx.com/'>condition</A> but have not been diagnosed. "Psoriasis has long been ]]></description>
<pubDate>Fri, 20 Aug 2010 08:00:00 -0400</pubDate>
<link>http://www.drugviews.com/articles.php?t=Skin-Condition-Associated-With-Depression-Anxiety-And-Suicidal-Feelings</link>
</item>

<item>
<title>UV-B Treatment May Improve Psoriasis And Vitamin D Levels</title>
<description><![CDATA[Treatment with narrow-band UV-B rays may increase serum levels of vitamin D in the wintertime while clearing psoriasis, according to a report in the August issue of Archives of Dermatology, <A HREF='http://www.1st-drug-rx.com/'>one</A> of the JAMA/Archives journals. Psoriasis affects 1.5 percent to 3 percent of the population, according to background <A HREF='http://www.druginformations.org/'>information</A> in the article. Abnormalities in vitamin D metabolism may be partly responsible for the development ]]></description>
<pubDate>Fri, 20 Aug 2010 08:00:00 -0400</pubDate>
<link>http://www.drugviews.com/articles.php?t=UV-B-Treatment-May-Improve-Psoriasis-And-Vitamin-D-Levels</link>
</item>

<item>
<title>Cetero Research expands Clinical Dermatology and Transdermal Delivery System services</title>
<description><![CDATA[Cetero Research, the leading early stage contract <A HREF='http://www.drug-care.info/'>research</A> <A HREF='http://www.druginformations.org/'>organization</A> (CRO), today announced the expansion of multiple Clinical Dermatology and Transdermal Delivery System (TDDS) <A HREF='http://www.datetopia.com/'>services</A> to four Cetero clinical facilities.]]></description>
<pubDate>Fri, 20 Aug 2010 01:02:00 -0400</pubDate>
<link>http://www.drugviews.com/articles.php?t=Cetero-Research-expands-Clinical-Dermatology-and-Transdermal-Delivery-System-services</link>
</item>

<item>
<title>Correspondence: History of eczema herpeticum is associated with the inability to induce human β‐defensin (HBD)‐2, HBD‐3 and cathelicidin in the skin of patients with atopic dermatitis</title>
<description><![CDATA[]]></description>
<pubDate>Fri, 20 Aug 2010 00:39:37 -0400</pubDate>
<link>http://www.drugviews.com/articles.php?t=Correspondence-History-of-eczema-herpeticum-is-associated-with-the-inability-to-induce-human-defensin-HBD-2-HBD-3-a</link>
</item>

</channel>
</rss>